Vote tally
quorum 5/3 ✓Description
RESOLUTION QUESTION: What molecular mechanisms drive the 8.1-fold increase in aducanumab brain delivery via FUS-mediated BBB opening? EMPIRICAL MILESTONES: Resolution requires: (1) physiologically-based pharmacokinetic (PBPK) modeling of aducanumab vs control antibodies predicting brain delivery efficiency based on FcRn binding affinity, isoelectric point, and molecular size; (2) experimental validation in humanized FcRn mouse models reproducing the 8.1-fold delivery difference; (3) structural comparison identifying which modifications (glycosylation This market resolves YES when the primary empirical milestone is met with peer-reviewed publication and independent replication.
Rationale
Domain: neurodegeneration. Priority score: 0.87. Importance: 0.85. Tractability: 0.90. SCIENTIFIC RATIONALE: The abstract reports dramatic enhancement of drug delivery but provides no mechanistic explanation for this specific magnitude of increase. Understanding these mechanisms is critical for optimizing therapeutic delivery protocols and predicting efficacy across different patient populations. Gap type RESOLUTION TIMELINE: 12–18 months. Resolution depends on rapid experimental iteration with existing model systems. LMSR LIQUIDITY RECOMMENDATION: 150 tokens. Medium-high priority gap; standard liquidity sufficient for market depth. Initial b-parameter should be set to token_cost/100 = 1.5 for LMSR scoring rule.
Pricing semantics
continuous_probability
Proposal cost: 150 tokens